Only one IPO – MiniMed – is braving the chilly winds of March 2026 and the uncertainty of conflict in the Middle East after the U.S. and Israel struck Iran on Saturday (Feb. 28, 2026). Wearable insulin pump pioneer MiniMed (MMED Proposed) is planning to price its large IPO on Wednesday night, March 4, 2026, to trade Thursday, March 5, on the NASDAQ.
MiniMed (MMED Proposed) is offering 28 million shares at a price range of $25.00 to $28.00 to raise $742.0 million, if priced at the $26.50 mid-point of its range.
Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are leading the joint book-runners’ team.
MiniMed is going public in a spin-off – also called a carve-out – from its parent, Medtronic.
After the IPO, Medtronic will still own a stake representing 90.03 percent of the voting power of MiniMed’s common stock eligible to vote in the election of its directors, the prospectus said.
Medtronic acquired MiniMed nearly 25 years ago.
The IPO marks MiniMed’s plan to return to the NASDAQ.
MiniMed (MMED Proposed), based in Northridge California, is a pioneer in the development of the wearable insulin pump – also known as an autonomous insulin device (AID) – and other technology.
MiniMed is not profitable, according to financial statements in the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.